@article{Robb_C-2020_8747,
title = {Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19},
author = {Robb, C. and Goepp, M. and Rossi, A. and Yao, C.},
month = {jul},
year = {2020},
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the novel coronavirus disease 2019 (COVID-19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine nor efficient treatment strategies against COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain and inflammation (common symptoms of COVID-19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxygenase enzymes. PGs can exert either pro- or anti-inflammatory effects depending on the inflammatory scenario. In this review, we implicate the potential roles that NSAIDs and PGs may play during SARS-CoV-2 infection and the development and progression of COVID-19.},
pages = {4899-4920},
volume = {177},
issue = {21},
journal = {British Journal of Pharmacology},
publisher = {Wiley},
url = {https://doi.org/10.1111/bph.15206},
}
